GLP-1 drugs are predicted to become the top-selling pharmaceutical class ever, with projected US sales of $150 billion by 2030. I have written multiple articles on GLP-1 drugs, highlighting their ...

The Inflation Reduction Act (IRA) of 2022 tasked the Centers for Medicare and Medicaid Services (CMS) to begin negotiating drug prices with manufacturers for the first time. CMS must consider several ...

The constant evolution of new COVID-19 variants makes it critical for clinicians to have multiple therapies in their arsenal for treating drug-resistant infections. Researchers have now discovered ...

Add Yahoo as a preferred source to see more of our stories on Google. Nitazenes, like this powder sample, are a class of synthetic opioids more potent than morphine and fentanyl. Joe Lamberti/The ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...

Please provide your email address to receive an email when new articles are posted on . Most of the studies compared TNF inhibitors with non-TNF-inhibitor DMARDs. The results may indicate that ...

Hyperactive signaling pathways of some aggressive blood cancer cells can be tamped down by a previously unrecognized protein complex, ensuring the cancer's survival. If one component of the complex is ...

In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...